The multi-center, open-label study is expected to enroll approximately 100 subjects with metastatic pancreatic cancer who have failed prior chemotherapy. Subjects are to receive daily oral monotherapy with Tyme's investigational drug therapy, SM-88.

In March 2018, Tyme announced the commencement of the trial. Up to thirty-five trial sites across the United States are expected to participate in the study.

Additional information regarding the trial can be found at the following link (www.clinicaltrials.gov). If you have questions beyond the information on that page, you can contact clinical@tymeinc.com.